IGF-1 HumanUnderstand the science
Where full-length human IGF-1 fits in the growth hormone pathway
2 numbered sourcesSource years 2006, 2026
Peptide bonds join amino acids into short chains called peptides. Longer chains can fold into hormones that carry signals between tissues. Human insulin-like growth factor 1 (IGF-1) is a 70-residue hormone with three internal disulfide bonds, which help hold the folded chain together. Mecasermin is the recombinant pharmaceutical form. How does providing IGF-1 differ from providing the growth hormone that ordinarily stimulates it? [1]
Growth hormone can tell the liver and other tissues to produce IGF-1. IGF-1 then activates its own receptor in target tissues and helps support processes involved in growth, including activity at the growth plates of bones. If the body's ability to respond to growth hormone is impaired, normal or elevated growth hormone can coexist with very low IGF-1. The U.S. prescribing information for mecasermin describes use in children at least two years old with severe primary IGF-1 deficiency, or with growth hormone gene deletion and neutralizing antibodies to growth hormone. [1]
Older primary evidence addressed how children with severe IGF-1 deficiency due to growth hormone insensitivity grew during treatment with recombinant IGF-1. In a long-term study, average height velocity increased in the first treatment year compared with pretreatment velocity. In later years growth was slower than in the first year, although the investigators reported increases over pretreatment velocity for several years. This shows the importance of measuring growth repeatedly instead of assuming that the first-year pace continues. [2]
No newer primary study of that foundational treatment comparison was identified for this article. The older trial was predominantly open-label and studied children with a defined, severe growth disorder. The indication and evidence concern full-length recombinant human IGF-1 in that setting. A low measurement on its own does not identify the reason the level is low, and the prescribing information distinguishes severe primary deficiency from low IGF-1 due to other causes. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
- 2.Chernausek SD et al. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. Journal of Clinical Endocrinology & Metabolism (publication 2006-12-27). (opens in a new tab)
pubmed.ncbi.nlm.nih.gov↩ Back to text
